Related Experiment Video
Updated: Aug 11, 2026
09:02
Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
Published on: July 31, 2016
Successful Treatment with Epcoritamab for Refractory Diffuse Large B-cell Lymphoma in a Dialysis-dependent Patient
Yuya Sasaki1, Keisuke Tanaka1, Hisako Nakamaki1
1Department of Hematology, Institute of Science Tokyo Hospital, Japan.
Internal Medicine (Tokyo, Japan)
|July 20, 2026
Summary
Epcoritamab shows promise for treating diffuse large B-cell lymphoma (DLBCL) in patients requiring dialysis. Careful monitoring is crucial due to potential side effects like necrosis, even with standard dosing.
Area of Science:
- Oncology
- Nephrology
- Pharmacology
Background:
- Epcoritamab is effective for diffuse large B-cell lymphoma (DLBCL).
- Safety data for epcoritamab in dialysis-dependent patients are lacking.
- Chronic kidney disease progression can lead to dialysis dependence.
Purpose of the Study:
- To evaluate the safety and efficacy of epcoritamab in a dialysis-dependent patient with refractory DLBCL.
- To assess the feasibility of standard-dose epcoritamab in this patient population.
Main Methods:
- Case report of a 53-year-old male with refractory DLBCL and end-stage renal disease requiring dialysis.
- Treatment with standard-dose epcoritamab.
- Monitoring for treatment response and adverse events.
Main Results:
- Achieved a complete response after three cycles of epcoritamab.
- Discontinued treatment after seven cycles due to lower leg necrosis.
- Necrosis was attributed to pre-existing arteriosclerosis.
Conclusions:
- Epcoritamab may be a feasible treatment option for dialysis-dependent patients with refractory DLBCL.
- Close monitoring for adverse events, such as necrosis, is essential.
- Individual patient factors, like comorbidities, necessitate careful consideration.
